Designations: | RKO-AS45-1 / RKO-ED |
Depositors: | MC Hollander, AJ Fornace |
Biosafety Level: | 2 [Contains CMV viral sequences ] |
Shipped: | frozen |
Medium & Serum: | See Propagation |
Growth Properties: | adherent |
Organism: | Homo sapiens (human) |
Morphology: | epithelial |
Source: | Organ: colon Disease: carcinoma |
Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
|
Oncogene: | p53 + (underexpressed) |
Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
Subculturing: | Subcultivation Ratio: A subcultivation ratio of 1:10 is recommended Medium Renewal: Every 2 to 3 days Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. |
Preservation: | culture medium 95%; DMSO, 5% |
Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003 recommended serum:ATCC 30-2020 parental cell line:ATCC CRL-2577 |
References: | 51464: Smith ML, et al. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene 13: 2255-2263, 1996. PubMed: 8950993 53491: Smith ML, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376-1380, 1994. PubMed: 7973727 53492: Bae I, et al. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. Cancer Res. 56: 840-847, 1996. PubMed: 8631022 |